Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer

NCT05845801 | Recruiting

• 1 other identifier: 3968
• Study Type: observational
• Target: 3,000
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of the present registry is the creation of a prospective registry collecting clinico-pathological and genomic data, along with survival outcomes, of individuals diagnosed with PDAC at or before the age of 55 years old. This registry is intended with the aim of using collected data for future clinical trials, both prospective and retrospective.

Conditions

PDAC - Pancreatic Ductal Adenocarcinoma

Outcome Measures

Primary Outcomes (1)

• Register of young PDAC patients

  Prospective collection of epidemiological, clinical, and pathological data of patients diagnosed with early-onset pancreatic cancer (EO-PDAC) - namely, individuals who have received a diagnosis of pancreatic cancer before, or at, the age of 55 years old.

  30 years

Interventions

Register OTHER

Prospective collection of epidemiological, clinical, and pathological data of patients diagnosed with early-onset pancreatic cancer (EO-PDAC) - namely, individuals who have received a diagnosis of pancreatic cancer before, or at, the age of 55 years old.

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

The target population is represented by individuals who have received a pathological diagnosis of pancreatic cancer before the age of 55 years old (namely, EO-PDAC patients). No subject will be financially compensated for their participation.

You may qualify if:

• Age ≤55 years old at the time of diagnosis of pancreatic cancer
• Age ≥ 18 years
• Written informed consent obtained.

You may not qualify if:

• Any pancreatic neoplasm other than pancreatic cancer (e.g. cholangiocarcinoma, ampullary cancer,duodenal cancer, non-invasive mucinous cystic neoplasm, pancreatic intra-epithelial neoplasia 1 and 2, non-invasive intraductal papillary mucinous neoplasm, serous cystic neoplasm, pseudo papillary solid tumor, neuroendocrine tumor)
• Absence of informed consent.
• Age \< 18 years or \> 55 years old at the time of diagnosis of pancreatic cancer

Sponsors & Collaborators

• Azienda Ospedaliera Universitaria Integrata Verona: lead

Study Sites (1)

AOUI Verona

Verona, 37134, Italy

RECRUITING

MeSH Terms

Interventions

Registries

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Records; Organization and Administration; Health Services Administration; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Central Study Contacts

Fabio Casciani

CONTACT

0458124671; fabio.casciani@univr.it

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Target Duration: 30 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 7, 2023
• First Posted: May 6, 2023
• Study Start: December 7, 2022
• Primary Completion (Estimated): September 30, 2052
• Study Completion (Estimated): September 30, 2052
• Last Updated: May 6, 2023

Record last verified: 2023-05

Locations

IT (1)